Allurion Expands Digital Offering For Patients and Providers in Response to COVID-19
NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, an established leader in the development of innovative, proven, and trusted weight loss experiences, is supporting customers around the world during COVID-19 with an expanded digital offering. The company’s weight loss program includes the world’s first and only procedureless gastric balloon, an individualized nutritional program, and a Bluetooth® smart scale and smartphone app that facilitate remote tracking. In response to recent data that indicates that individuals with obesity are at higher risk of poorer outcomes from COVID-19 and that quarantine measures may lead to weight gain, the company has expanded access to telenutrition for both existing…
Start-ups that could become the Middle East’s next big ventures
CAIRO: Following initial news of the $3.1 billion deal in March 2019, US ride-hailing firm Uber completed its acquisition of Dubai-based vehicle-for-hire company Careem at the beginning of January 2020. Middle East and North Africa (MENA) startups have been getting much-needed funds to scale up their businesses, and 2019 seems to have set the bar high. During the first half of last year, startups in the region received $471 million in investments, up 66 percent from the $283 million invested over the same period in 2018. Given the steadily growing number of MENA startups, it remains extremely difficult to spot…
NHS leaders have spoken, they want transparency!
Ahmed and I know as well as anyone that transparent, collaborative working within the NHS is the most effective way to get the highest standard of work done, in the most efficient way, and importantly make patients well again. The last few years that we’ve witnessed within the NHS have been some of its hardest. As budgets are stretched to breaking point and every penny is scrutinised, rather than coming together as one NHS, pools of money have been separated and allocated to individual Trusts. This has led to a separation of resources, staff and ultimately formed silos of communication…
Fractyl Announces First-Ever Commercial Availability of Revita for Type 2 Diabetes in Partnership with Leading UK Private Clinic
LEXINGTON, Mass., January 28, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced its first commercial partnership with HCA Healthcare UK (United Kingdom), making its Revita® treatment commercially available for the first time for patients with type 2 diabetes. HCA Healthcare UK is the largest provider of privately funded healthcare in the UK and is part of the US-based HCA Healthcare, the world’s largest private hospital group. Revita is a first-in-class intervention designed to target insulin resistance and metabolic disease progression by resetting key pathways in the gut that drive metabolic disease. This minimally-invasive, outpatient, endoscopic procedure is a non-drug and…